Literature DB >> 26581499

Purinergic signalling in brain ischemia.

Felicita Pedata1, Ilaria Dettori2, Elisabetta Coppi3, Alessia Melani2, Irene Fusco2, Renato Corradetti2, Anna Maria Pugliese2.   

Abstract

Ischemia is a multifactorial pathology characterized by different events evolving in the time. After ischemia a primary damage due to the early massive increase of extracellular glutamate is followed by activation of resident immune cells, i.e microglia, and production or activation of inflammation mediators. Protracted neuroinflammation is now recognized as the predominant mechanism of secondary brain injury progression. Extracellular concentrations of ATP and adenosine in the brain increase dramatically during ischemia in concentrations able to stimulate their respective specific P2 and P1 receptors. Both ATP P2 and adenosine P1 receptor subtypes exert important roles in ischemia. Although adenosine exerts a clear neuroprotective effect through A1 receptors during ischemia, the use of selective A1 agonists is hampered by undesirable peripheral effects. Evidence up to now in literature indicate that A2A receptor antagonists provide protection centrally by reducing excitotoxicity, while agonists at A2A (and possibly also A2B) and A3 receptors provide protection by controlling massive infiltration and neuroinflammation in the hours and days after brain ischemia. Among P2X receptors most evidence indicate that P2X7 receptor contribute to the damage induced by the ischemic insult due to intracellular Ca(2+) loading in central cells and facilitation of glutamate release. Antagonism of P2X7 receptors might represent a new treatment to attenuate brain damage and to promote proliferation and maturation of brain immature resident cells that can promote tissue repair following cerebral ischemia. Among P2Y receptors, antagonists of P2Y12 receptors are of value because of their antiplatelet activity and possibly because of additional anti-inflammatory effects. Moreover strategies that modify adenosine or ATP concentrations at injury sites might be of value to limit damage after ischemia. This article is part of the Special Issue entitled 'Purines in Neurodegeneration and Neuroregeneration'.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ATP; Adenosine; Cerebral ischemia; Oxygen glucose deprivation; P1 receptors; P2 receptors

Mesh:

Substances:

Year:  2015        PMID: 26581499     DOI: 10.1016/j.neuropharm.2015.11.007

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  52 in total

1.  Caffeine exposure ameliorates acute ischemic cell death in avian developing retina.

Authors:  D Pereira-Figueiredo; R Brito; D S M Araújo; A A Nascimento; E S B Lyra; A M S S Cheibub; A D Pereira Netto; A L M Ventura; R Paes-de-Carvalho; K C Calaza
Journal:  Purinergic Signal       Date:  2020-02-20       Impact factor: 3.765

Review 2.  Neuronal P2X7 Receptors Revisited: Do They Really Exist?

Authors:  Peter Illes; Tahir Muhammad Khan; Patrizia Rubini
Journal:  J Neurosci       Date:  2017-07-26       Impact factor: 6.167

Review 3.  The neuroprotective effects of caffeine in neurodegenerative diseases.

Authors:  Mahshad Kolahdouzan; Mazen J Hamadeh
Journal:  CNS Neurosci Ther       Date:  2017-04       Impact factor: 5.243

4.  Adenosine receptors as markers of brain iron deficiency: Implications for Restless Legs Syndrome.

Authors:  César Quiroz; Seema Gulyani; Wan Ruiqian; Jordi Bonaventura; Roy Cutler; Virginia Pearson; Richard P Allen; Christopher J Earley; Mark P Mattson; Sergi Ferré
Journal:  Neuropharmacology       Date:  2016-09-04       Impact factor: 5.250

Review 5.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

6.  Blockade and knock-out of CALHM1 channels attenuate ischemic brain damage.

Authors:  Abraham Cisneros-Mejorado; Miroslav Gottlieb; Asier Ruiz; Juan C Chara; Alberto Pérez-Samartín; Philippe Marambaud; Carlos Matute
Journal:  J Cereb Blood Flow Metab       Date:  2017-06-09       Impact factor: 6.200

Review 7.  Pathological overproduction: the bad side of adenosine.

Authors:  Pier Andrea Borea; Stefania Gessi; Stefania Merighi; Fabrizio Vincenzi; Katia Varani
Journal:  Br J Pharmacol       Date:  2017-03-31       Impact factor: 8.739

8.  Adenosine A1 receptor-mediated protection of mouse hippocampal synaptic transmission against oxygen and/or glucose deprivation: a comparative study.

Authors:  Masahito Kawamura; David N Ruskin; Susan A Masino
Journal:  J Neurophysiol       Date:  2019-06-26       Impact factor: 2.714

Review 9.  Role of adenosine A2A receptors in motor control: relevance to Parkinson's disease and dyskinesia.

Authors:  Annalisa Pinna; Marcello Serra; Micaela Morelli; Nicola Simola
Journal:  J Neural Transm (Vienna)       Date:  2018-02-02       Impact factor: 3.575

10.  Adenosine A1 receptor antagonist rolofylline alleviates axonopathy caused by human Tau ΔK280.

Authors:  Frank J A Dennissen; Marta Anglada-Huguet; Astrid Sydow; Eckhard Mandelkow; Eva-Maria Mandelkow
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.